Just days after President Trump imposed broad restrictions on communications, meetings, travel and public appearances at the ...

Cell therapy biotech Aurion is moving forward with plans to IPO despite a pending lawsuit from one of its existing investors.

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

The author of the seminal cancer biography The Emperor Of All Maladies and the co-founder of LinkedIn are looking to connect ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

The FDA has tapped Sara Brenner to serve as acting commissioner as it awaits new leadership from the Trump administration to ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...

Japan’s Nippon Shinyaku is continuing to scoop up the international rights to some intriguing drugs, this time penning a $686 ...

Despite making up a sizable chunk of entry-level employees at the biggest U.S. biopharmas, the share of east Asian Americans drops dramatically as you move up the ranks. | Despite making up a sizable ...